BMRN · BioMarin Pharmaceutical Inc.
AI read · Bad for BMRN
The AI's read
These costs will lower the profit BioMarin expects to report, and its earlier full-year forecast did not include the deal. The company plans to update that forecast with its third-quarter results. Alesta's research work may have future value, but this filing gives no expected sales or clinical results to balance the costs. The estimates are preliminary and may change.